Ethics
This article was originally published in RAJ Devices
Executive Summary
Stanford University in US moves to limit industry influence
You may also be interested in...
Keeping Track: US FDA Clears Esperion’s Nexletol, Baudax’ Anjeso, Agile’s Twirla
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
Esperion’s Nexletol Reaches The Cholesterol Market Priced To Sell
Esperion obtained an on-time approval of Nexletol (bempedoic acid) for a pair of LDL cholesterol-lowering indications on 21 February.
Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports